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Mills,' Duc J. Vugia,' Dennis D. Juranek,& and Deborah A. Levy&
We conducted a randomized, triple-blinded home drinking water intervention trial to determine if a large study
could be undertaken while successfully blinding participants. Households were randomized 50:50 to use exter-
nally identical active or sham treatment devices. We measured the effectiveness of blinding of participants by
using a published blinding index in which values >0.5 indicate successful blinding. The principal health out-
come measured was Ahighly credible gastrointestinal illness@ (HCGI). Participants (n=236) from 77 households
were successfully blinded to their treatment assignment. At the end of the study, the blinding index was 0.64
(95% confidence interval 0.51-0.78). There were 103 episodes of HCGI during 10,790 person-days at risk in
the sham group and 82 episodes during 11,380 person-days at risk in the active treatment group. The inci-
dence rate ratio of disease (adjusted for the clustered sampling) was 1.32 (95% CI 0.75, 2.33) and the attribut-
able risk was 0.24 (95% CI -0.33, 0.57). These data confirm that participants can be successfully blinded to
treatment group assignment during a randomized trial of an in-home drinking water intervention.
n 1991, Payment and colleagues described a randomized,
controlled intervention trial designed to evaluate whether
the consumption of tap water treated conventionally to meet
regulatory standards affects incidence of gastrointestinal (GI)
illness (1). In this trial, reverse osmosis filters were installed in
299 households (1,206 persons), and another 307 households
(1,202 persons) were followed as controls, with no device
installed. After prospective follow-up over a 15-month period,
the investigators concluded that 35% of the self-reported GI ill-
ness was attributable to tap water consumption. A second trial
conducted several years later included treatment groups receiv-
ing regular tap water, tap water from a continuously purged
tap; bottled treatment plant water; and purified bottled plant
water (2). This second study attributed 14% to 40% of GI ill-
ness to consumption of tap water that met Canadian water
treatment standards. Because participants in these studies were
not blinded to their treatment group assignments, GI illness
may have been overreported by subjects in the tap water
groups.
In 1996, the Safe Drinking Water Act of 1974 (3) was
amended to require the Centers for Disease Control and Pre-
vention (CDC) and the Environmental Protection Agency
(EPA) to provide a national estimate of waterborne infectious
disease in the United States. In the late 1990s, these agencies
funded a large, randomized trial to evaluate the risk for GI ill-
ness from the consumption of tap water treated to meet all fed-
eral drinking water standards. As a preliminary step in the
determination of the national estimate, CDC and EPA funded
this pilot study to determine the feasibility of water interven-
tion trials blinding participants to group assignment.
We report the results of the Pilot Water Evaluation Trial
(Pilot WET), a randomized, controlled, triple-blinded interven-
tion trial performed in 1999 in households in Contra Costa
County in northern California. The primary objective of the
trial was to assess whether, for 4 months, participants could be
successfully blinded to group assignment, a (sham or active)
water treatment device installed underneath the kitchen sink.
Secondary objectives included estimating rates of highly credi-
ble gastrointestinal illness (HCGI) and other health outcomes
and determining the feasibility of performing a similar trial on
a larger scale.
Methods
The study and the informed consent process were
reviewed, approved, and monitored by six Institutional Review
Boards (Human Subjects Protection Committees) from the
investigators= institutions (University of California, Berkeley;
the University of California, San Francisco; the California
Department of Health Services; and Public Health Foundation
Enterprises, Inc.) and the funding agencies (CDC and EPA).
*University of California Berkeley, Berkeley, California, USA; HCalifornia
Emerging Infections Program, Berkeley, California, USA; I University of
California San Francisco, School of Medicine, San Francisco,
California, USA; 'California Department of Health Services, Berkeley,
California, USA; and  &Centers for Disease Control and Prevention,
Atlanta, Georgia, USA
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Study Area, Water Supply and Water Distribution System
The study area included single-family dwellings served by
the Contra Costa Water District. The treatment plant serving
the study area used standard conventional treatment with chlo-
ramination. A new ozonation plant was completed during the
study period, so that after May 1999 the water supply was also
ozonated. Source water from the San Joaquin River delta con-
tained agricultural and industrial runoff and pathogens, includ-
ing Cryptosporidium. (More detailed water characterization for
the district may be found at http://www.epa.gov/enviro/html/
icr/utility/report/CA0710003961023144135.html). Nonethe-
less, the finished water meets all federal and state drinking
water treatment standards and requirements.
Recruitment, Enrollment, and Compensation of 
Households
Households were recruited by the Survey Research Center
at the University of California, Berkeley, through hand deliv-
ery of information packets describing the trial, and by tele-
phone recruitment with a reverse directory in the targeted
enrollment areas. To be eligible for the trial, families were
required to own their homes, use municipal tap water as the
principal drinking water source, and have no household mem-
bers with a serious immunocompromising condition (such as
HIV/AIDS or cancer). Households received $40 on enrollment
and an additional $160 in installments on the return of com-
pleted health diaries throughout the trial. The first device was
installed in March 1999 and the final device in October 1999.
Each family was asked to participate for 16 weeks.
One member of each household, designated the  Aindex
respondent,@ was responsible for communications between the
household and the Survey Research Center. The index respon-
dent was the adult member of the household who was in the
best position to complete health diaries for other household
members who were unable to do so. For 16 weeks, the index
respondent mailed completed questionnaires every 2 weeks to
the Survey Research Center.
Randomization and Blinding
Two random sequences were generated to allocate house-
holds 50:50 to active or sham filtration devices in blocks of 20.
Blocking ensured approximate balance in the number of house-
holds per device as participants accrued. One study investiga-
tor, who remained unblinded throughout the trial and had no
role in data analyses, prepared coded labels from the sequences
and sent them to the manufacturer; the manufacturer perma-
nently affixed the labels to the devices. All other study investi-
gators, the plumbing contractor who installed the devices, and
the study subjects were blinded as to the household device
assignment throughout the trial, including the analysis phase,
resulting in a triple-blinded trial.
Statistical Methods: Blinding Index and Sample Size
The sample size requirement was based on the primary aim
of the trial: to determine if subjects could be blinded to water
filtration device type. The effectiveness of blinding was quanti-
fied by the Blinding Index (BI) of James et al. (4), which can
be expressed as BI = p x (r/2) + q, where p is the proportion
who attempt to guess their device assignment, 0 < p < 1; r is
the ratio, among those who attempt guesses, of the proportions
of observed and expected guesses; and q = 1 - p is the propor-
tion of subjects who do not attempt to guess (i.e., report they
Adon=t know@). When r/2 = 0, BI = q, and when r/2 = 1, BI = 1;
thus 0 < BI < 1. If correct guesses are weighted by 0.0 as rec-
ommended (4), then r/2 depends only on incorrect guesses. If,
in addition, the weights and expected proportions are equal for
all incorrect guesses, the term p x (r/2) equals the proportion of
incorrect guesses; otherwise, p x (r/2) approximates the pro-
portion of incorrect guesses. Thus, BI can be the same or
nearly the same as the sum of the proportions of incorrect and
Adon=t know@ responses. The expected values used in the ratio r
are calculated under the hypothesis that assignments and
guesses are independent (i.e., the subjects are blinded); under
this hypothesis r/2 = 0.5, whereas when the observed propor-
tion of incorrect guesses exceeds the expected proportion r/2 >
0.5. Assuming that both incorrect and Adon=t know@ responses
are consistent with blinding, James et al. (4) suggest that when
the BI is >0.5 the subjects have been blinded successfully on
average.
We designed the study to test the null hypothesis with a
type I error rate of 0.05, a type II error rate of 0.10, and a vari-
ance estimated by BI(1 - BI). In simulations, the distribution of
the BI was found to be approximately binomial (data not
shown), and this distribution was assumed for variance estima-
tion when the necessary sample size was calculated. Assuming
an average household size of 2.4 persons, on the basis of cen-
sus data, and an intrahousehold correlation of 0.60, based on
the work of Donner, Birkett, and Buck (5), 80 households, 40
per group, were required.
Active and Sham Water Treatment Devices
Devices for our trial were purchased from Freshwater Sys-
tems, Australia, and installed by Assured Water Products, Inc.,
a licensed plumbing firm based in Contra Costa County. The
devices were designed to be externally identical and to differ
only in their ability to remove microorganisms from water.
The active water treatment device contained a 1-micron
absolute prefilter cartridge and a UV lamp secured in a quartz
sleeve that permitted transmission of UV light. The lamp was
designed to emit UV light at 254 nm (optimum for disinfec-
tion) with a total minimum dose of 38,000 m watt-sec/cm2 to
reduce postfiltration bacteria and viruses by  >99% (6). The
manufacturer provided written certification that the lamp
would emit UV light above this level for 1 year.
The sham device contained an empty filter housing and a
UV lamp in a glass sleeve that prevented the transmission of
UV light to the water. Inside the empty filter housing, a plastic
tube was glued to the inlet to circulate incoming water through-
out the empty housing tank to prevent stagnation. Both devices
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and an alarm that would sound in the event of failure of the UV
lamp or power supply. The devices, installed under the kitchen
sink on the cold water line, included a separate drinking water
tap at the sink. Both devices provided a water flow through the
tap of 5 liters per minute. The cost of the water treatment
device, including plumbing expenses, was approximately $988
per household.
Blinding Outcomes
Every 2 weeks, participants aged >12 years were asked to
report on a questionnaire one of five possible responses: “It is
definitely the active water treatment device;” “It is probably
the active water treatment device;” “It is probably not the
active water treatment device;” “It is definitely not the active
water treatment device;” or “I'm not sure.” To accommodate
the blinding index, these responses were collapsed to three cat-
egories: “The active device,” “Not the active device,” or “I
don=t know.” We report the BI and 95% confidence interval
(CI) based on the week 16 responses, both for index respon-
dents alone and for all household respondents. We adjusted the
latter CI for the intrahousehold correlation, r=0.60, specified a
priori. If the correlation were 0.0, no adjustment would be
needed and all participants would be independent observations.
If the correlation were 1.0, then each household would be
treated as only one observation, since all members of a house-
hold would be perfectly correlated in their responses. To sup-
plement these analyses, we also tested, via the 95% CI, the
within-assignment null hypotheses that the proportions suc-
cessfully blinded (i.e., those with "don=t know@ or incorrect
responses) were <0.5. We did not solicit the blinding status of
investigators or contractors. We include the analyses showing
only the index respondents to represent a situation in which the
correlation coefficient is equal to 0.0. 
Finally, to evaluate whether unblinding of participants
influenced their reporting of HCGI episodes, we stratified by
guess group (active, sham, and don=t know) and estimated,
within strata, rates and incidence rate ratios (IRR) of HCGI for
the sham and active devices. These analyses were performed
by using guesses from the end of study (week 16) question-
naire.
Health Outcomes
Participants aged >12 years were asked to record each day
in diaries whether they had symptoms such as nausea, vomit-
ing, diarrhea, abdominal cramps, cough, and fever; index
respondents were asked to record these data for children and
other household members who might need assistance. The
principal health outcome measured in the trial was similar to
the Ahighly credible gastrointestinal illness@ reported by Pay-
ment et al. A new episode, defined before the analysis was per-
formed, was defined as any of the following four conditions,
preceded by at least 6 HCGI-free days: 1) vomiting; 2) watery
diarrhea; 3) soft diarrhea and abdominal cramps occurring
together on any day; or 4) nausea and abdominal cramps occur-
ring together on any day.
Episodes during the first 6 days of the study were also
included, without the restriction of 6 disease-free days before
the study. If HCGI information was missing for a particular
day, that day was evaluated as HCGI-free for the purpose of
identifying subsequent episodes of HCGI. HCGI data were
analyzed by Poisson regression adjusted for the intrahousehold
correlation introduced by the clustered sampling design. We
examined the duration of HCGI episodes, in days, by device.
The attributable risk for HCGI from drinking water was calcu-
lated as (IRR B 1) / (IRR), where IRR is the incidence rate ratio
of the rate of HCGI in the sham group compared with that in
the active group.
Water Consumption
Water consumption was self-reported by using data col-
lected in questions inserted into the final health questionnaire.
Participants were asked to estimate (in numbers of 8-oz.
glasses) their consumption of drinking water at home (sepa-
rately through the study device and through all other sources at
home) and outside the home. Participants were provided with
water bottles and encouraged to carry water from the home
device for use when outside the home. Mean water consump-
tion was compared by study group via the two-sample t-test.
Results
Recruitment and Enrollment
Flyers describing the trial were distributed to 29,415
homes. Of 573 households screened after contacting us for
more information, 439 (77%) were ineligible for the trial. The
most common reasons for ineligibility included using bottled
water (21%) or a home water filter device (13%); no children
in the household (17%); and preexisting problems with the
kitchen plumbing (14%). Of the 134 eligible households, 47
(35%) declined to participate. We were able to install a treat-
ment device in 80 (92%) of the 87 consenting households.
Eighty households were needed to meet the sample size
requirements discussed below.
Three households were excluded from the trial after the
device was installed: one operated a day-care center in the
home; at the second, household members objected to the taste
of the water after installation; and at the third, household mem-
bers failed to submit any health diaries. The remaining 77
households (38 active; 39 sham) with 236 participants (118
active; 118 sham) provided partial or complete data on blind-
ing and health outcomes and form the basis for the analyses
presented in this report.
Completeness of Health Data Collection from Participants
For each participant, the maximum number of health dia-
ries that could be collected was eight (biweekly over 16 weeks)
with 112 possible days of data (16 weeks times 7 days). Sev-
enty-four (96%) of the 77 households completed all 16 weeks
of the trial. In the active group, 879 (85%) biweekly question-
naires were received from a possible 1,032 questionnaires. In32 Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002
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the sham group, 861 (89%) of a possible 968 questionnaires
were received. In the diaries received, health data were pro-
vided for 91% of possible days by participants in the active
group and for 86% in the sham group.
Randomization and Baseline Characteristics (Table 1)
The groups were comparable at baseline as measured by
the distribution of age, gender, health status, and preexisting
gastrointestinal complaints. The average number of partici-
pants per household in the sham group was 3.03 and in the
active group was 3.11 (p=0.80). The average number of chil-
dren <12 years of age in each household was 0.73 in the sham
group and 0.75 in the active group (p=0.86). Of the index
respondents, 67% were female.
Water Consumption (Exposure) Patterns during the Trial
Participants in the sham group reported drinking an aver-
age of 3.1 glasses of unheated water per day from the study
device, and those in the active group drank 3.0 glasses per day
(p=0.73). There was no difference in the total amount of drink-
ing water consumed by the participants from all sources (mean
6.8 glasses per day in the sham group; 7.4 glasses per day in
the active group, p=0.46).
Effectiveness of Blinding of Participants (Table 2)
The blinding index was 0.64 (95% CI 0.51-0.78) when the
week 16 questionnaires of 145 participants >12 years of age
were analyzed (Table 2). This finding, adjusted for an intra-
household correlation ( r) of 0.60 was highly robust to the
choice of correlation coefficients: at r=0.40 the CI widens by
0.02, and at r=0.80 it narrows by 0.02. The blinding index was
0.65 (95% CI 0.53-0.76) when the 64 index participants were
analyzed. Overall, most subjects guessed  Aactive@ as their
device assignment (50%); 33% guessed Adon=t know,@ and the
rest guessed Asham.@
Within device group, 83% (95% CI 74%-92%) of partici-
pants assigned to the sham group appeared to be successfully
blinded (i.e., guessed Adon=t know@ or Aactive@), compared with
43% (95% CI 32%-54%) of those assigned to the active group.
Results among index participants were similar to the overall
findings.
Analysis of Gastrointestinal Illnesses (Tables 3 and 4)
In the sham group there were 103 episodes of HCGI and
10,790 days on which these subjects were at risk for HCGI
(3.48 episodes per person-year; adjusted 95% CI 2.26,-5.34).
In the active group there were 82 episodes of HCGI during
11,380 days at risk (2.63 episodes per person-year; adjusted
95% CI 1.82, 3.79). The IRR was 1.32 (adjusted 95% CI 0.75,
-2.33) when all household respondents were analyzed and 1.09
(95% CI 0.63, -1.90) when data were analyzed only from the
index respondent in each household. Data were also analyzed
for the component definitions based on the first day of each
episode of HCGI (vomiting, watery diarrhea, soft diarrhea with
abdominal cramps, and nausea with abdominal cramps) (Table
3). If drinking water were the cause of the reported increase in
gastrointestinal disease, the adjusted rate ratio for episodes of
HCGI would suggest an attributable risk of 0.24 (95% CI -0.33,
-0.57).
HCGI episodes were typically brief; they did not differ in
duration between the two groups (p=0.23). The median dura-
tion of episodes in the active group was 1 day (range 1 to 40
days; interquartile range 1 to 2 days). The median duration of
episodes in the sham group was 2 days (range 1 to 40 days;
interquartile range 1 to 3 days).
Among those guessing that they were using a sham device
and also among the group of participants guessing  Adon=t
Table 1. Baseline characteristics of 236 participants in Pilot Water
Evaluation Trial
Characteristic
Sham
(n = 118)
Active
(n = 118)
Age (Years) n (%) n (%)
  <11 28 (24) 29 (25)
  12-19 10 (8) 13 (11)
  20-29 9 (8) 4 (3)
  30-39 22 (19) 18 (15)
  40-49 21 (18) 24 (20)
  50-59 16 (14) 14 (12)
 >60 12 (10) 16 (14)
Sex (%) n (%) n (%)
  Female 57 (48) 56 (48)
  Male 61 (52) 62 (52)
Prior medical conditions n (%) n (%)
  Crohn=s disease 1 (1) 0 (0)
  Diverticulitis 1 (1) 3 (3)
  Frequent heartburn 5 (4) 8 (7)
  Irritable bowel syndrome 7 (6) 2 (2)
  Milk intolerance 4 (3) 5 (4)
  Stomach ulcer 5 (4) 4 (3)
  Ulcerative colitis 0 (0) 1 (1)
  Migraine headaches 14 (12) 13 (11)
Self-assessment of current health n (%) n (%)
  Excellent 42 (36) 41 (35)
  Very good 54 (46) 53 (45)
  Good 20 (17) 20 (17)
  Fair 2 (2) 4 (3)
  Poor 0 (0) 0 (0)
Current medical conditions (prior 7 
days) n (%) n (%)
  Abdominal cramps 19 (16) 15 (13)
  Diarrhea 14 (12) 13 (11)
  Nausea 16 (14) 11 (9)
  Vomiting 2 (2) 3 (3)
  Fever 6 (5) 5 (4)
  Pregnant 1 (1) 1 (1)Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002 33
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know@ the reported rates of HCGI were nearly identical in the
two device groups (Table 4). However, among subjects guess-
ing that they were using an active device, the rates of illness
were higher among those actually using the sham. A similar
pattern (higher rate in the sham group) was seen among sub-
jects who did not complete a final blinding questionnaire.
Quality Control
Early in the trial we learned that five devices (two active
and three sham) had been installed in reverse. The normal flow
of water in the device is through the filter first and then through
the UV light chamber. In these five devices, the flow passed
through the UV chamber first and then through the filter. For
all potentially reversed devices (i.e., those installed before the
discovery of this reversal), we either directly inspected them or
inspected photographs obtained at installation as part of our
routine quality control procedures. Although these devices still
provided treatment of water, they had not been installed
according to protocol and were replaced with identical devices
(sham or active) connected correctly. We have retained these
households in our analyses. 
Discussion
This pilot study is the first in the United States to evaluate
blinding in a randomized, controlled trial of drinking water.
Our findings suggest that at least two thirds of participants
remained blinded to device assignment throughout the 16-
week trial. The actual level of blinding was probably greater,
since some subjects may have guessed their device assignment
by chance alone. 
Our trial was undertaken as the first step in planning a
larger trial to evaluate the risk for infection from drinking tap
water fully treated to meet conventional regulatory standards
in the United States. Without the ability to blind the partici-
pants in such intervention trials, the results of any subsequent
larger studies intended to evaluate health effects attributable to
drinking water would remain controversial. Our data suggest
that subjects were effectively blinded throughout the pilot trial.
We estimated that a higher proportion of subjects was blinded
in the sham group (83%) than in the active group (43%); how-
ever, in the active group the 95% CI included 50%, indicating
that correct responses may be attributable to chance.
A secondary goal of the trial was to compare gastrointesti-
nal illness rates in the two groups. Although the rate of gas-
trointestinal illness was higher in the sham group than in the
treatment group, this difference was not statistically signifi-
cant. The relative rates of illness observed overall and in spe-
cific subgroups (gender and age) were very similar to those
reported in an earlier, larger randomized trial in Canada, which
found a statistically significant difference between the active
and control groups (1). Preliminary results from a similar trial
in Australia, which also was blinded, found no difference in
the rates of disease in the active and sham groups (7).
Effectiveness of Participant Blinding 
Despite the widespread use of participant blinding in inter-
vention trials, little methodologic literature is available with
Table 2. Final (Week 16) Device Blinding Questionnaire, Pilot Water
Evaluation Trial
All participants (>12 years of age) who completed final questionnaire
Guess
Sham device 
group (%)
Active device 
group (%) Total (%)
Sham 12 (17.4) 12 (15.8) 24 (16.6)
Active 30 (43.5) 43 (56.6) 73 (50.3)
Don=t know 27 (39.1) 21 (27.6) 48 (33.1)
Total* 69 (100.0) 76 (100.0) 145 (100.0)
Index respondents only+
Guess
Sham device 
group (%)
Active device 
group (%) Total (%)
Sham 5 (16.1) 5 (15.2) 10 (15.6)
Active 13 (41.9) 19 (57.6) 32 (50.0)
Don=t know 13 (41.9) 9 (27.3) 22 (34.4)
Total 31 (100.0) 33 (100.0) 64 (100.0)
*Does not include 21 participants from the sham device group and 13 participants
from the active device group who did not complete the final blinding questionnaire.
+Blinding index for all participants (adjusted for intrahousehold correlation,
r=0.60)=0.64 (95% confidence interval [CI] 0.51B0.78). Blinding index for index
respondents alone = 0.65 (95% CI 0.53B0.76).
Table 3. Episodesa of highly credible gastrointestinal illness (HCGI)
and days of illness, Pilot Water Evaluation Trial
Sham 
device 
group
Active 
device 
group Total
Total episodes of HCGI, defined byb 103 82 185
  Vomiting 18 30 48
  Watery diarrhea 73 42 115
  Soft diarrhea with abdominal cramps 7 6 13
  Nausea with abdominal cramps 16 17 33
Total days of HCGI, defined byb 261 190 451
  Vomiting 35 78 113
  Watery diarrhea 207 99 306
  Soft diarrhea with abdominal cramps  8 8 16
  Nausea with abdominal cramps 31 30 61
Total days at risk for HCGI episodes 10,790 11,380 22,170
Total days of observation 11,642 12,036 23,678
aA new episode was defined as the presence of any of four definitions of HCGI,
preceded by 6 HCGI-free days. The difference in total episodes of HCGI was the
principal a priori health outcome measure for the study.   
bBecause individual participants could report multiple definitions of HCGI on the
same day, the total episodes of HCGI (and total days of HCGI) are less than the sums
of the individual definitions.34 Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002
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which to measure its effectiveness. In the absence of successful
blinding, biases may explain the results of a trial. For example,
subjects aware that they are not receiving an intervention (i.e.,
the sham group) could, intentionally or not, report a higher (or
lower) frequency of disease. 
Our measurement of blinding is based on work by James
(4). If 100% of the participants in a study guess their treatment
assignment correctly, the BI would be 0.0 (complete unblind-
ing). If 50% of the participants guess correctly, the BI would be
0.5 (random guessing). If 100% of the participants were to
guess Adon=t know,@ the BI would be 1.0 (perfect blinding). Our
trial provides evidence that blinding, as measured by the blind-
ing index, can be maintained successfully during an in-home
drinking water intervention trial. Subjects in both groups were
more likely to guess that they had the active device; we specu-
late that this may be related to the fact that both active and pla-
cebo devices warmed the water during long periods when
water was not being drawn from the tap. This warming could
have led participants in both groups to believe they were using
the active device. Our study lasted only 4 months, and the
effectiveness of blinding may decline during a prolonged trial.
Drinking water intervention trials conducted for extended peri-
ods should also assess blinding throughout the trial. The fre-
quency of such questioning of participants should be designed
to avoid raising awareness of treatment group assignment,
which might increase unblinding. 
Table 4. Rates of highly credible gastrointestinal illness (HCGI) episodes and incidence rate ratios (IRR)a for all respondents and index
respondents, by respondent guess about device assignment, week 16,b Pilot Water Evaluation Trial
All Repondents Index Respondents
Sham device Active device Sham device Active device
Guess = ASham@
   Episodes of HCGI 4 4 3 1
   Person-time (person-years) 3 3 1 1
   No. of respondents 12 12 5 5
   Rate (95% CI) 1.2 (0.3B4.8) 1.1 (0.5B2.7) 2.1 (0.7B6.6) 0.7 (0.1B4.8)
   IRR for sham vs. active (95% CI) 1.0 (0.2B5.4) 3.16 (0.3B30.4)
Guess = AActive@
   Episodes of HCGI 30 30 6 15
   Person-time (person-years) 8 12 4 5
   No. of respondents 30 43 13 19
   Rate (95% CI) 3.6 (2.1B6.3) 2.5 (1.3B4.5) 1.6 (0.7B3.6) 2.8 (1.7B4.6)
   IRR for sham vs. active (95% CI) 1.5 (0.7B3.3) 0.6 (0.2B1.5)
Guess = ADon=t know@
   Episodes of HCGI 18 15 10 6
   Person-time (person-years) 8 6 4 3
   No. of respondents 27 21 13 9
   Rate (95% CI) 2.4  (1.2B4.6) 2.5 (1.1B5.5) 2.7 (1.5B5.1) 2.3 (1.0B5.2)
   IRR for sham vs.active (95% CI) 1.0 (0.3B2.7) 1.2 (0.4B3.3)
All guesses
   Episodes of HCGI 52 49 19 22
   Person-time (person-years) 19 22 9 9
   No. of respondents 69 76 31 33
   Rate (95% CI) 2.7 (1.7B4.3) 2.2 (1.5B3.4) 2.2 (1.4B3.4) 2.3 (1.5B3.5)
   IRR for sham vs.active (95% CI) 1.2 (0.6B2.2) 0.9 (0.5B1.7)
No guess given
   Episodes of HCGI 12 5 5 2
   Person-time (person-years) 4 2 1 1
   No. of respondents 21 13 8 5
   Rate (95% CI) 3.3 (1.1B9.7) 2.7 (1.1B6.9) 5.4 (2.6B11.3) 3.0 (0.7B11.8)
   IRR for sham vs. active (95% CI) 1.2 (0.3B5.1) 1.8 (0.4B8.8)
aRates of HCGI and IRR were calculated by Poisson regression and were adjusted for the intrahousehold correlation introduced by the sampling design.
bRespondents for the blinding questionnaires were all aged >12 years.Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002 35
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Comparison with Payment=s Prior Intervention Trial
The rates of illness we observed (as measured by HCGI)
were higher than those reported in the earlier work of Payment
et al.(1). Our trial was much shorter than Payment=s (4 months
vs. 15 months). Conceivably, subjects in both active and sham
groups are more likely to report (or even overreport) illness
early in the trial, when enrollment and participation instruc-
tions have been recently given and emphasized. Another possi-
ble explanation for the difference we observed in the rates of
illness between the groups could be that certain persons con-
tributed a disproportionate number of illnesses. However, our
data did not support this explanation, since the distribution of
number of episodes did not differ between the two groups. 
We detected no significant differences in water consump-
tion patterns of the two groups. If any differences in consump-
tion of water outside the home did exist, a conservative bias
would have been introduced into our results that would likely
have attenuated any difference in observed health effects.
Although our definition of HCGI was patterned after the
work of Payment et al. (1), there were some differences. In the
earlier work, symptoms were reported to the index respondent,
who completed all the questionnaires for all subjects. In our
study, each participant aged $12 years completed his or her
own health questionnaires. Payment et al. excluded episodes
believed to have other plausible etiologies; we included all epi-
sodes. We asked participants to indicate diarrhea on days in
which they had two or more loose stools; Payment et al. do not
specify the definition of diarrhea. Finally, Payment et al. used
the term @liquid@ stool; our term was Awatery.@
Payment=s point estimate of the effect (rate ratio = 1.38) is
similar to ours (rate ratio = 1.32). Payment reported an attribut-
able fraction of 35% (of HCGI attributable to drinking water
consumption); our study=s point estimate of the attributable
fraction was 24%.
Limitations
We selected for the trial only families who owned their
homes so that consent would be needed only from the partici-
pating family and not also from a landlord. This selection may
have led to the recruitment of subjects of higher socioeconomic
status than the target population. However, any bias would not
affect the internal validity of the study because the subjects
were randomized.
Knowledge of experimental group assignment can influ-
ence self-reported endpoints in clinical trials, thereby reducing
the internal validity of the findings. The experimental group
assignment might be revealed to participants through distin-
guishing features of the intervention (e.g., after installation of
the filter, the household water tastes different), through acci-
dental communication of the assignment by study personnel
(e.g., the plumber), and, especially in trials with long follow-
up, through early or repeated occurrence of an episodic out-
come or its symptoms (e.g., HCGI). 
Several limitations should be considered in interpreting the
health results of this trial. First, it was conducted in a single
municipality that received its water from a challenged surface
water source and treated water with chloramination. As is typi-
cal of randomized, controlled trials, our study relied on volun-
teers, which hampers external generalizations. As a result of
randomization, however, its strength lies in its internal validity
(enabling comparison of active and sham groups without fear
of selection bias). Data from a series of studies of various
designs conducted in various locations are necessary for the
development of a national estimate of waterborne disease. This
is the approach being used by CDC and EPA. Finally, we pro-
vided a treatment device for only one tap in each household. If
participants obtained drinking water from other taps (despite
our instructions to avoid this as much as possible), our study
may underestimate any attributable risk. Use of devices that
treated all water entering each household was neither practi-
cally nor economically feasible. 
Our sample size in this pilot study was determined based
on the blinding index. Our study was not designed to be large
enough to detect a difference in health (as measured by HCGI)
between the sham and active groups of the magnitude previ-
ously reported by Payment. If a study were designed with 80%
power to detect a true reduction in HCGI to 1.3 episodes/per-
son-year from a level of 2.6 in the sham group, observation of
200 households (of approximatly three persons per household)
would be required for one year of observation (based on a two-
sided 0.05-level test adjusted for intrahousehold correlation
[r=0.60]). Additionally, although our study did not collect the
data necessary to evaluate the severity of the HCGI episodes,
our data indicate that about half the illnesses in both groups
were short-lived (only 1 or 2 days long). We suggest that future
studies include measurement of episodes associated with lost
time at work or school or resulting in calls or visits to physi-
cians, clinics, or emergency rooms. Such measurement will
allow better assessment of the public health impact of any dif-
ferences attributable to drinking water consumption. 
One theoretical explanation for the results we observed
could be that the sham device somehow degraded the drinking
water. In a limited water sampling program (data not shown),
we did not find evidence to support this. Additionally, in a
large study with the same device in Australia, no difference in
health effects was found between the active and sham device
groups, suggesting that degradation of the water by the sham
device is not a likely explanation for our findings (7).
Finally, drinking water proceeds in a complicated path
from environmental sources, through water treatment and dis-
tribution systems, through internal pipes in the home, and
eventually to a consumer=s tap. Drinking water intervention tri-
als that use in-home treatment devices cannot isolate the
source of any specific site of contamination. Rather, such trials
can only help provide evidence to suggest whether further
evaluation of the drinking water pathway may be necessary in
specific settings.36 Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002
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Conclusion
Our data suggest that subjects were effectively blinded
throughout a 4-month trial of an in-home drinking water inter-
vention. Although the rate of gastrointestinal illness was higher
in the sham group than in the treatment group, this difference
was not statistically significant, and the trial was not designed
to detect a difference of the magnitude observed. The relative
rates of illness overall were very similar to those reported in an
earlier, larger randomized trial in Canada, which did report sta-
tistically significant differences in HCGI between the groups.
Our findings suggest that it will be possible to conduct larger
blinded, randomized trials to evaluate health effects related to
tap water consumption. 
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